Jeffrey W. Albers, Director at Blueprint Medicines Corp (BPMC), sold 39,010 shares at $82.76 ($3.2M) on 2024-01-25, disclosed to the SEC on 2024-01-29.
Scheduled sale ($3.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $81.16 | 6,086 | $494K | 15.4% |
| 2 | $81.16 | 6,086 | $494K | 15.4% |
| 3 | $81.70 | 10,890 | $890K | 27.8% |
| 4 | $82.76 | 7,924 | $656K | 20.5% |
| 5 | $82.76 | 7,924 | $656K | 20.5% |
| 6 | $83.57 | 100 |
| $8K |
| 0.3% |
| Total | $81.97 avg | 39,010 | $3.2M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $296K | — | Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |